PURE EXTRACTS TECHN. CORP
Pure Extracts Technologies Corp. engages in the extraction and processing of cannabis and hemp to produce oils and various derivative products in Canada. The company offers THC and CBD based extracted oils. It also engages in the development and commercialization of functional wellness products and psychedelic medical products. Pure Extracts Technologies Corp. is headquartered in Pemberton, Canad… Read more
PURE EXTRACTS TECHN. CORP (PUX) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, PURE EXTRACTS TECHN. CORP (PUX) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
PURE EXTRACTS TECHN. CORP - Net Assets Trend (None–None)
This chart illustrates how PURE EXTRACTS TECHN. CORP's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for PURE EXTRACTS TECHN. CORP (None–None)
The table below shows the annual net assets of PURE EXTRACTS TECHN. CORP from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to PURE EXTRACTS TECHN. CORP's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
PURE EXTRACTS TECHN. CORP Competitors by Market Cap
The table below lists competitors of PURE EXTRACTS TECHN. CORP ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
NORTHEAST UTILITIES
BE:NWJ
|
$529.15K |
|
Gentor Resources Inc
PINK:GNTOF
|
$529.23K |
|
BOLT BIOTHERAP. DL-00001
F:6LP
|
$529.61K |
|
Dowa Holdings Co. Ltd
DU:DMI
|
$530.24K |
|
Inventage Lab Inc.
KO:389470
|
$528.54K |
|
Atmofizer Technologies Inc
PINK:ATMFF
|
$527.96K |
|
CELANESE-A (DG3.SG)
STU:DG3
|
$527.78K |
|
ARKEMA - Dusseldorf Stock Exchang
DU:V1S
|
$527.25K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in PURE EXTRACTS TECHN. CORP's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares PURE EXTRACTS TECHN. CORP's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently PURE EXTRACTS TECHN. CORP utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares PURE EXTRACTS TECHN. CORP's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $9,244,379,027
- Average return on equity (ROE) among peers: -92.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| PURE EXTRACTS TECHN. CORP (PUX) | €- | N/A | N/A | $528.88K |
| 26U (26U) | $6.75 Million | -514.32% | 1.08x | $243.78K |
| 27N0 (27N0) | $11.56 Million | -0.93% | 0.00x | $4.26K |
| China Resources Pharmaceutical Group Limited (640) | $90.18 Billion | 4.60% | 1.68x | $987.66 Million |
| CIG WIRELESS (6CW) | $27.09 Million | -110.19% | 3.19x | $77.40 Million |
| Solasia Pharma K.K (9SO) | $1.16 Billion | -167.91% | 0.18x | $35.57 Million |
| Apontis Pharma AG (APPH) | $3.46 Million | -34.21% | 7.59x | $11.70 Million |
| Akebia Therapeutics Inc (AX9) | $635.93 Million | -22.58% | 0.57x | $283.56 Million |
| Biofrontera AG (B8FK) | $-12.89 Million | 0.00% | 0.00x | $3.73 Million |
| AVALA RES (CVJ) | $91.87 Million | -27.32% | 0.11x | $113.22K |
| Deciphera Pharmaceuticals Inc (D05) | $341.69 Million | -52.37% | 0.33x | $2.11 Billion |